Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM), a medical technology and healthcare company focused on neurohealth therapies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Keith Sullivan, President and CEO, will deliver a presentation on Tuesday, August 12, 2025, at 1:30 PM ET.

The presentation will be accessible to registered attendees and presenting companies through the conference portal for 14 days following the event.

Neuronetics (NASDAQ: STIM) announced significant findings published in JAACAP Open regarding the effectiveness of NeuroStar TMS therapy in treating adolescent and young adult depression. The study, based on the world's largest TMS outcomes dataset, analyzed 1,283 patients aged 12-21 and found that approximately 70% of patients showed clinically meaningful improvement.

Since receiving FDA clearance in March 2024 for treating adolescents aged 15-21, NeuroStar has seen a one-third increase in adolescent treatments. The research demonstrated similar efficacy to adult populations, with less than 1% reporting worsening symptoms. The study is particularly significant as only two FDA-approved medications exist for adolescent depression, both carrying major safety warnings.

Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, before market open.

The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. Investors can access the live webcast through the provided link, and telephone participants are encouraged to register and join 10 minutes before the event starts.

Neuronetics (NASDAQ: STIM) has appointed Steven Pfanstiel as its new Chief Financial Officer, effective July 15, 2025. Pfanstiel, who brings over 20 years of healthcare experience, replaces Steve Furlong, who will remain as Senior Advisor to the CEO until his retirement on March 31, 2026.

Pfanstiel most recently served as CFO and COO at Marinus Pharmaceuticals and has held senior financial roles at Lifescan, Optinose, and Johnson & Johnson. As part of his appointment, he received an inducement grant of 400,000 restricted stock units with specified vesting schedules.

The company has reaffirmed its guidance for Q2 and full year 2025, expecting to achieve positive cash flow in Q3 2025. The outlook is supported by successful Greenbrook operations integration and progress in key growth initiatives.

Neuronetics (NASDAQ: STIM) announced inducement awards for new non-executive employee Jeff Jones, approved under NASDAQ Listing Rule 5635(c)(4). The compensation package includes 30,000 Performance Restricted Stock Units (PRSUs) tied to achieving cash flow breakeven in Q3 and Q4 2025, 27,500 PRSUs vesting in three installments through 2027 based on cash balance targets, and 112,500 Restricted Stock Units (RSUs) vesting equally over three years. The awards, granted under the Company's 2020 Inducement Incentive Plan, are contingent on continued employment through applicable vesting dates.

Neuronetics (NASDAQ: STIM) announced its participation as a Silver Sponsor at the 13th Annual Clinical TMS Society Meeting in San Diego from June 11-14, 2025. The company will present two significant posters using data from TrakStar, the largest real-world TMS outcomes database. The first presentation by Dr. Eleanor Cole focuses on TMS effectiveness in elderly adults with Major Depressive Disorder, while the second by Cory Anderson compares clinical outcomes between NeuroStar's Figure-8 coil and Brainsway's H-coil across 200 Greenbrook centers. Additionally, Greenbrook Mental Wellness Centers, a Neuronetics subsidiary, has launched a program evaluating personalized qEEG-informed protocols for TMS therapy using the NeuroStar system, with promising initial feasibility results.

Neuronetics (NASDAQ: STIM) announced its upcoming inclusion in both the Russell 2000® and Russell 3000® Indexes, effective June 30, 2025, following the annual reconstitution of Russell indexes. The Russell 3000® Index comprises the 3,000 largest U.S. public companies by market cap, while the Russell 2000® focuses on small-cap companies. These indexes, managed by FTSE Russell, serve as benchmarks for approximately $10.6 trillion in assets. CEO Keith J. Sullivan highlighted this inclusion as validation of their strategic vision in mental healthcare delivery, noting the company's expansion through NeuroStar technology and Greenbrook clinic network. The company expects to achieve positive cash flow in 2025 while maintaining strong growth through their operating model.

Neuronetics (NASDAQ: STIM) has launched the first National TMS Therapy Awareness Day, scheduled annually for May 14 during Mental Health Awareness Month. The initiative aims to raise awareness about transcranial magnetic stimulation (TMS) as a non-drug treatment option for major depressive disorder (MDD), depression with anxiety, and OCD. NeuroStar, the leading TMS therapy in the US, received FDA clearance for adolescent treatment in 2024, expanding its reach beyond adult patients. The treatment is covered by insurance plans for over 300 million people, including Medicare and Tricare. The company will showcase patient stories, including that of Kristen Gingrich, a licensed clinical social worker who found relief through NeuroStar TMS after struggling with depression. Additionally, NeuroStar will present research data at the 2025 American Psychiatric Association Annual Meeting, focusing on TMS protocols and treatment efficacy.

Neuronetics (NASDAQ: STIM) reported strong Q1 2025 financial results with revenue of $32.0 million, up 84% year-over-year, primarily driven by the Greenbrook acquisition. Key highlights include:

- U.S. clinic revenue: $18.7M (Greenbrook) - Treatment session revenue: $9.6M - NeuroStar System revenue: $2.8M

The company completed an $18.9M secondary offering in February 2025. Notable developments include CFO Steve Furlong's planned retirement in March 2026, major insurance coverage expansions for adolescent TMS treatment, and achieving over 202,000 global patients treated. Despite a Q1 net loss of $(12.7M), Neuronetics projects becoming cash flow positive in Q3 2025.

For 2025, Neuronetics updated guidance to $149.0M-$155.0M in total revenue, with Q2 2025 expected revenue between $36.0M-$38.0M. The company anticipates year-end cash above $20.0M.